8. ハンチントン病 Huntington disease Clinical trials / Disease details

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

diseases per page:

Showing 1 to 10 of 242 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05686551 (ClinicalTrials.gov)	January 30, 2023	16/12/2022	GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With ...	A Phase II, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, ...	Huntington Disease	Drug: Tominersen 60 mg;Drug: Placebo;Drug: Tominersen 100 mg	Hoffmann-La Roche	NULL	Recruiting	25 Years	50 Years	All	360	Phase 2	United States;Spain
2	EUCTR2022-001991-32-ES (EUCTR)	22/12/2022	23/12/2022	A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals with Prodromal ...	A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, ...	Huntington's disease(HD) MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntingto ...	Product Code: RO7234292 INN or Proposed INN: Tominersen Other descriptive name: N/A	Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La R ...	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 2	Canada;Argentina;Spain;Australia;United Kingdom;New Zealand;Japan
3	NCT05655520 (ClinicalTrials.gov)	December 14, 2022	9/12/2022	A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Diseas ...	A Phase 3, Multicenter, Open-label Safety Study to Evaluate the Long-term Safety and Tolerability of ...	Huntington Disease	Drug: SAGE-718	Sage Therapeutics	NULL	Recruiting	25 Years	65 Years	All	300	Phase 3	United States
4	NCT05541627 (ClinicalTrials.gov)	October 12, 2022	13/9/2022	A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disea ...	An Open-Label Phase I/II Dose Finding Study to Evaluate the Safety, Tolerability, and Preliminary Ef ...	Huntington Disease	Genetic: AB-1001 Gene Therapy	Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio)	NULL	Recruiting	18 Years	65 Years	All	18	Phase 1/Phase 2	France
5	NCT05475483 (ClinicalTrials.gov)	August 2, 2022	22/7/2022	Efficacy and Safety on SOM3355 in Huntington's Disease Chorea	Phase IIb, Randomized, Double-blind, Placebo-controlled Study in Parallel Groups Assessing the Effic ...	Huntington Chorea	Drug: SOM3355 capsules;Drug: Placebo capsules	SOM Innovation Biotech SA	NULL	Recruiting	21 Years	N/A	All	129	Phase 2	France;Germany;Italy;Poland;Spain;Switzerland;United Kingdom
6	EUCTR2021-003052-16-FR (EUCTR)	20/07/2022	08/12/2021	Phase I/II Safety and Tolerability Study of striatal administration of BV-101 in adult subjects with ...	An Open-Label Phase I/II Dose Finding Study to evaluate the Safety, Tolerability, and Preliminary Ef ...	Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's ...	Product Name: AAVrh10.CAG.hCYP46A1 Product Code: BV-101 INN or Proposed INN: AAVrh10.CAG.hCYP46A1 Other ...	Brainvectis	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	18	Phase 1;Phase 2	United States;France
7	NCT05358821 (ClinicalTrials.gov)	June 22, 2022	27/4/2022	A Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's ...	A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Stud ...	Huntington Disease	Drug: SAGE-718;Drug: Placebo	Sage Therapeutics	NULL	Recruiting	25 Years	65 Years	All	80	Phase 2	United States
8	NCT04478734 (ClinicalTrials.gov)	June 1, 2022	11/2/2020	Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease	Multicentric Trial on the Use of Combined Therapy of Thiamine and Biotine in Patients With Huntingto ...	Huntington Disease	Drug: Moderate doses of Thiamine y Biotin;Drug: High doses of Thiamine y Biotin	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	Ciberned (Centro de Investigación Biomédica en Red)	Not yet recruiting	18 Years	N/A	All	24	Phase 2	Spain
9	EUCTR2021-003852-18-DE (EUCTR)	06/05/2022	18/02/2022	A Phase 2A study of PTC518 in patients with Huntington's Disease	A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY O ...	Huntington’s disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's ...	Product Name: PTC518 tablet 5 mg Product Code: PTC518 INN or Proposed INN: Not available Other descripti ...	PTC Therapeutics, INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	162	Phase 2	France;United States;Australia;Netherlands;Germany;United Kingdom
10	NCT05358717 (ClinicalTrials.gov)	April 25, 2022	27/4/2022	A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)	A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy o ...	Huntington Disease	Drug: PTC518;Drug: Placebo	PTC Therapeutics	NULL	Recruiting	25 Years	N/A	All	162	Phase 2	United States;Australia;France;Germany;Netherlands;United Kingdom

First Previous1 2 3 4 5…25Next Last